Indinavir is a protease inhibitor used in the treatment of HIV infected individuals and as post-exposure prophylaxis. Indinavir is associated with various adverse effects including gastrointestinal, a lipodystrophy syndrome and nephrolithiasis. We describe indirect hyperbilirubinemia as an adverse effect of indinavir in a person on post-exposure prophylaxis (PEP).
|Original language||English (US)|
|Number of pages||2|
|Journal||Journal of Association of Physicians of India|
|State||Published - Oct 2002|
ASJC Scopus subject areas